FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
What happened
In August 2025, FDA reviewed the website https://coretrustlabs.com and found it offered compounded retatrutide, semaglutide and tirzepatide. FDA said compounded retatrutide is an unapproved new drug and misbranded because it does not meet conditions for compounding exemptions and its labeling lacks adequate directions for use. FDA also said website claims that semaglutide was FDA-approved in 2017 and tirzepatide in 2022 are false or misleading because compounded drugs are not FDA-approved.
What FDA found
The company sold compounded retatrutide without an FDA-approved drug application.
FDCA sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]Compounded retatrutide does not qualify for the 503A or 503B compounding exemptions because retatrutide is not on the relevant FDA bulk drug lists and is not a component of an approved drug or on the shortage list.
FDCA sections 503A(b)(1)(A)(i) and 503B(a)(2)(A)(i) [21 U.S.C. §§ 353a(b)(1)(A)(i), 353b(a)(2)(A)(i)]The retatrutide labeling lacks adequate directions for use, so the drug is misbranded.
FDCA section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website says semaglutide and tirzepatide were FDA-approved, which is false or misleading for compounded products.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The company introduced or delivered these misbranded and unapproved drugs into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells Trust Labs to take immediate action to correct the violations, including stopping the misleading FDA-approval language. The company must respond in writing within 15 working days to FDA's Office of Compounding Quality and Compliance, describing steps taken, preventive actions, and supporting documents, or explain why it disagrees.
Who should pay attention
- telehealth and online pharmacies selling compounded weight-loss drugs
- compounders using bulk drug substances not on FDA lists
- brands or clinics that promote compounded semaglutide or tirzepatide
This is a summary. Read the original letter on fda.gov.